LEAD-472

N/A

Report date: 2023/08/02 17:09:58

Base Information

Drug NameLEAD-472
Drug Alias NameLEAD-472
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsTumor necrosis factor agonists
TargetsTumor necrosis factor
Therapy Area/IndicationsLung NeoplasmsThyroid NeoplasmsTesticular Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLeadartis SL
China Registration ClassN/A

Develop Information

Active CompaniesLeadartis SL
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsThyroid NeoplasmsTesticular Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A